# EDGAR Filing Document

**Accession Number:** 0002030763
**File Stem:** 0001641172-25-026035
**Filing Date:** 2025-8
**Character Count:** 17408
**Document Hash:** 41afd83cead2a6e38736eaa9139ca6a8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-026035.hdr.sgml**: 20250829

**ACCESSION NUMBER**: 0001641172-25-026035

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 33

**CONFORMED PERIOD OF REPORT**: 20250828

**ITEM INFORMATION**: Entry into a Material Definitive Agreement

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250829

**DATE AS OF CHANGE**: 20250829

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Wellgistics Health, Inc.
- **CENTRAL INDEX KEY:** 0002030763
- **STANDARD INDUSTRIAL CLASSIFICATION:** WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
- **ORGANIZATION NAME:** 07 Trade & Services
- **EIN:** 933264234
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-42530
- **FILM NUMBER:** 251281873

**BUSINESS ADDRESS:**
- **STREET 1:** 3000 BAYPORT DRIVE SUITE 950
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607
- **BUSINESS PHONE:** 1-843-302-1785

**MAIL ADDRESS:**
- **STREET 1:** 3000 BAYPORT DRIVE SUITE 950
- **CITY:** TAMPA
- **STATE:** FL
- **ZIP:** 33607

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Danam Health, Inc
- **DATE OF NAME CHANGE:** 20240717

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **August 28, 2025**

**WELLGISTICS HEALTH, INC.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-42530** | **93-3264234** |
| (State or other jurisdiction<br> of incorporation) | (Commission<br> File Number) | (I.R.S. Employer<br> Identification No.) |

---

**3000 Bayport Drive**

**Suite 950**

**Tampa, FL 33607**

(Address of principal executive officers) (Zip Code)

**(844) 203-6092**

(Registrant's telephone number, including area code)

**Not applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock, par value $.0001 per share** | **WGRX** | **The Nasdaq Stock Market LLC**<br> **(Nasdaq Capital Market)** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 1.01. Entry into a Material Definitive Agreement.**

On August 28, 2025, the Company entered into a Business Loan and Security Agreement with Agile Capital Funding, LLC for a principal amount of $1,300,000 (the "***Agile Loan***"). The Agile Loan is effective as of August 26, 2025, and matures on April 8, 2026. The interest charge of the Agile Loan is equal to $572,000, assuming all payments are made on time. The Company has agreed to repay the Agile Loan in weekly installments of $58,500, and it may be prepaid subject to payment of prepayment fee equal to the aggregate and actual amount of interest (at the contract rate of interest) that would be paid through the maturity date. A portion of the Agile Loan was used to satisfy previously outstanding obligations under (i) that certain Business Loan and Security Agreement dated as of May 14, 2025, among Agile Capital Funding, LLC, the Company, and Wellgistics, LLC and (ii) that certain Agreement for the Purchase and Sale of Future Receipts dated June 25, 2025 by and between the Company and Agile Capital Funding, LLC. The Company received approximately $500,000 in cash proceeds. The Company intends to utilize the net proceeds of the Agile Loan for general working capital purposes. The Agile Loan is secured by certain assets of the Company not otherwise secured in its other financing arrangements.

The foregoing description of the Agile Loan does not purport to be complete and is qualified in its entirety by reference to the full text of the Agile Loan, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

**Item 7.01. Regulation FD Disclosure.**

On August 27, 2025, the Company issued a press release regarding the introduction of a fully customizable artificial intelligence engine integrated into the Company's tech and hub platform. The press release is filed as Exhibit 99.1 hereto and is incorporated herein by reference.

The press release shall not be deemed "filed" for any purpose, including for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "***Exchange Act***"), or otherwise subject to the liabilities of such Section 18. The information in this Item 7.01, as well as Exhibit 99.1, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended or the Exchange Act regardless of any general incorporation language in such filing.

The press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. With the exception of historical matters, the matters discussed in the press releases include forward-looking statements within the meaning of applicable securities laws. Such forward-looking statements include, among others, statements regarding the Company's projects, potential financial performance, and growth opportunities. The words "believes," "expects," "intends," "plans," "anticipates," "hopes," "likely," "will," and similar expressions are intended to identify certain of these forward-looking statements. These statements are based on the Company's expectations and involve risks, uncertainties and other important factors that could cause the actual results performance or achievements of the Company (or entities in which the Company has interests), or industry results, to differ materially from future results, performance or achievements expressed or implied by such forward-looking statements. Certain factors that could cause the Company's actual future results to differ materially from those discussed are noted in connection with such statements, but other unanticipated factors could arise. Certain risks regarding the Company's forward-looking statements are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), including an extensive discussion of these risks in the Company's Annual Report on Form 10-K filed with the SEC on March 25, 2025, and subsequent Quarterly Reports on Form 10-Q filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements which reflect management's view only as of the date of this Form 8-K. The Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, conditions or circumstances.

**Item 9.01 Financial Statements and Exhibits.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit Number** | **Description** |
| 10.1# | [Business Loan and Security Agreement dated as of August 26, 2025, among Agile Capital Funding, LLC, Wellgistics Health, Inc., and Wellgistics, LLC.](ex10-1.htm) |
| 99.1 | [Press Release by Wellgistics Health, Inc., dated August 27, 2025.](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded with the Inline XBRL document). |

---

# As permitted by Regulation S-K, Item 601(b)(10)(iv) of the Securities Exchange Act of 1934, as amended, certain confidential portions of this exhibit have been redacted from the publicly filed document. The Company agrees to furnish supplementally an unredacted copy of the exhibit to the Securities and Exchange Commission upon its request.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Wellgistics Health, Inc.** | **Wellgistics Health, Inc.** |
| Dated: August 29, 2025 | By: | */s/ Mark DiSiena* |
|  |  | Mark DiSiena |
|  |  | Chief Financial Officer |

---

## Exhibit 10.1

**Exhibit 10.1**

![](ex10-1_001.jpg)

![](ex10-1_002.jpg)

![](ex10-1_003.jpg)

![](ex10-1_004.jpg)

![](ex10-1_005.jpg)

![](ex10-1_006.jpg)

![](ex10-1_007.jpg)

![](ex10-1_008.jpg)

![](ex10-1_009.jpg)

![](ex10-1_010.jpg)

![](ex10-1_011.jpg)

![](ex10-1_012.jpg)

![](ex10-1_013.jpg)

![](ex10-1_014.jpg)

![](ex10-1_015.jpg)

![](ex10-1_016.jpg)

![](ex10-1_017.jpg)

![](ex10-1_018.jpg)

![](ex10-1_019.jpg)

## Exhibit 99.1

**Exhibit 99.1**

**Wellgistics Health Introduces HubRx AI: Advancing the AI-Powered Prescription Ecosystem**

**TAMPA, FL / <u>ACCESS Newswire</u> / August 27, 2025 /** Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the introduction of **HubRx AI -** a fully customizable AI engine built to streamline prescription hub services, reduce costs, and improve patient outcomes.

**What HubRx AI Delivers**

HubRx AI is an in-house, full-stack AI agent engine that integrates with Wellgistics Health's platform. It connects seamlessly with leading LLMs (ChatGPT, Claude, Gemini, Grok, and others) and enables the rapid design, customization, and training of specialized bots that power programs, functions, tasks, and workflows - all while safeguarding patient data with strict privacy, security, and compliance controls

The HubRx AI command center enables operators to design, create, manage, and scale intelligent agents that automate and optimize core hub services, including:

● Patient Onboarding & Adherence

● Eligibility & Benefits Verification

● Prior Authorization

● Claims Management

● Customer Service & Sales

As HubRx AI establishes its footprint through live deployments, Wellgistics Health intends to scale access across prescription healthcare stakeholders - paving the way for SaaS, membership, subscription, and licensing models that create recurring, high-margin revenue streams and long-term sustainable growth.

**The WGRX Full-Stack Ecosystem: Digital + Physical Rails**

Wellgistics Health combines advanced AI with a nationwide supply chain and distribution fulfillment network - all built and run in-house, not outsourced**.**

**Technology (Digital Script Flow with AI Intelligence):**

● **Einstein Rx AI** - AI engine for clinical decision support and safety optimization.

● **Wellgistics Hub (formerly DelivMeds)** - Digital routing infrastructure ensuring prescriptions move seamlessly from any source to any patient.

● **HubRx AI** - AI-powered hub services engine automating benefit verification, authorizations, and patient adherence workflows.

**Physical Infrastructure:**

● **Distribution Network** - Provides the physical rails that move medications reliably from manufacturer to patient.

● **Community Pharmacies** - A trusted network of 6,500+ independent pharmacies across all 50 states, ensuring scale and local access for patients in need of insurance-covered medications.

● **In-House Pharmacy** - Cash-pay and telemedicine fulfillment for direct-to-consumer solutions.

**Executive Commentary**

"Unlike traditional PBMs or siloed tech platforms, Wellgistics Health owns the full stack," said **Dr. Shafaat Pirani, Chief Clinical Officer of Wellgistics Health**. "Einstein Rx AI ensures the right clinical decision, HubRx AI optimizes the digital flow, and Wellgistics Hub intelligently routes prescriptions. Together, with our national distribution network and pharmacy infrastructure, we ensure medications reach patients faster, smarter, and more affordably."

"Wellgistics continues to forge ahead as a forward thinker," said **Brian Norton, Chief Executive Officer of Wellgistics Health**. "We ask the hard questions about why healthcare is so slow and expensive, and we're determined to change that. By building a vertically integrated ecosystem, we eliminate costly third parties, reduce friction and delays, and ensure the patient drug journey is more secure and controlled. We see a healthcare system in transition - one where the old ways of doing business are fading, and end-to-end AI-driven solutions will define the future. That's the future Wellgistics is building toward."

Wellgistics Health plans to begin implementation and onboarding for HubRx AI in Q4 2025, with full rollout and scaled operations expected in early 2026.

**Market Need & Opportunity**

The U.S. prescription drug market now exceeds $800 billion annually¹, with employers spending more than $315 billion on pharmacy benefits². Yet inefficiencies, claim denials, and opaque PBM practices contribute to more than $30 billion in avoidable waste each year³.

At the same time, the global pharma hub services market - encompassing platforms that support patient onboarding, benefits verification, prior authorization, adherence, and case management - is projected to reach $5.7 billion by 2030, growing at a CAGR of 9.9%⁴.

By embedding AI into every step of the prescription journey, Wellgistics Health is positioning HubRx AI to meet this demand, helping independent pharmacies, pharmaceutical manufacturers, and payors deliver:

● Faster access for patients

● Lower costs for employers and payors

● Stronger margins for pharmacies

**About Wellgistics Health**

Wellgistics Health delivers medications from manufacturer to patient - faster, smarter, and more affordably. Its integrated platform connects more than 6,500 independent pharmacies and 200 U.S. manufacturers, offering wholesale distribution, digital prescription routing, and AI-driven hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health provides compliant, end-to-end solutions designed to restore access, transparency, and trust in U.S. healthcare.

**Forward-Looking Statements**

This press release may contain forward-looking statements. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When Wellgistics Health uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. These forward-looking statements include, without limitation, statements regarding Wellgistics Health's strategy and descriptions of its future operations, prospects, and plans. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause actual results to differ materially from Wellgistics Health's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, market conditions and other risks detailed in our reports and statements filed with the SEC. Investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in Wellgistics Health's filings with the SEC, available at <u>www.sec.gov</u>.

**Media Contact:**<u>media@wellgisticshealth.com</u><br> **Investor Relations:**<u>investors@wellgisticshealth.com</u>

**Investor Relations Contact:**

Skyline Corporate Communications Group, LLC

Scott Powell, President

1177 Avenue of the Americas, 5th Floor

New York, NY 10036

Office: (646) 893-5835

Email: <u>info@skylineccg.com</u>

**References**

&nbsp;&nbsp;&nbsp;&nbsp;1. IQVIA
 Institute, *The Use of Medicines in the U.S.* (2023)

2. Kaiser
 Family Foundation, *Employer Health Benefits Survey* (2023)

3. Pharmaceutical
 Care Management Association (PCMA) + CMS estimates on claims waste (2022-2023)

4. Grand
 View Research, *Pharma Hub Services Market Report* (2024)

**SOURCE:** Wellgistics Health, Inc.